Established in 1976, JB Chemicals and Pharmaceuticals is one of India's fastest-growing pharmaceutical companies. With a diverse portfolio spanning gastroenterology, dermatology, nephrology, respiratory, virology, diabetes, and Nicotine Replacement Therapy, they focus on delivering patient-friendly formulations. Beyond India, their key markets include Russia and South Africa, with exports to over 30 countries, including the USA. JBCPL is a global leader in medicated lozenges, ranking among the top five manufacturers worldwide. Their seven state-of-the-art manufacturing facilities, including a dedicated lozenge plant, are certified by major global regulators. Over the years, they have expanded through strategic acquisitions, collaborations, and regulatory approvals, strengthening their R&D and market presence. With a commitment to innovation and excellence, JB Chemicals and Pharmaceuticals continues to grow as a trusted pharmaceutical brand worldwide.
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 3568 12.6% | 3170 27.8% | 2481 13.0% | 2196 20.1% | 1829 7.4% | 1704 17.3% | 1452 4.8% | 1386 8.1% | 1282 9.4% | 1171 8.6% | 1078 20.8% | 893 -43.4% | 1578 72.4% | 916 18.9% | 770 4.4% | 737 - |
Net Operating Income (INR Cr) | 3484 10.63% | 3149 29.91% | 2424 18.69% | 2043 15.09% | 1775 8.00% | 1643 16.67% | 1408 4.77% | 1344 11.07% | 1210 5.78% | 1144 11.97% | 1022 17.98% | 866 8.02% | 802 -9.98% | 891 20.54% | 739 3.34% | 715 27.71% |
Profit (INR Cr) | 553 34.8% | 410 6.4% | 385 -14.0% | 448 64.7% | 272 40.6% | 193 39.9% | 138 -24.8% | 184 13.2% | 163 61.9% | 100 63.3% | 62 -22.6% | 79 -88.3% | 678 386.6% | 139 17.3% | 119 361.9% | 26 - |
Assets (INR Cr) | 3321 8.2% | 3071 38.9% | 2210 17.8% | 1876 26.6% | 1482 -2.3% | 1517 2.0% | 1487 3.9% | 1431 2.7% | 1393 22.8% | 1134 -1.2% | 1148 6.5% | 1079 2.8% | 1049 20.8% | 868 23.2% | 705 8.8% | 648 - |
Net Worth (INR Cr) | 2923 17.9% | 2480 16.2% | 2134 17.9% | 1810 26.1% | 1435 -3.0% | 1480 2.7% | 1442 5.7% | 1364 15.2% | 1184 19.0% | 995 -4.6% | 1043 3.3% | 1010 5.2% | 960 40.5% | 684 21.3% | 564 20.7% | 467 4.4% |
Employee Cost (INR Cr) | 601 10.7% | 543 23.7% | 439 29.0% | 341 5.5% | 323 12.1% | 288 14.8% | 251 15.5% | 217 24.0% | 175 9.9% | 160 11.1% | 144 10.5% | 130 15.4% | 113 -9.8% | 125 18.7% | 105 7.4% | 98 - |
Interest Cost (INR Cr) | 44 | 36 | 5 | 7 | 3 | 5 | 3 | 5 | 11 | 7 | 6 | 4 | 24 | 10 | 12 | 15 |
Cash & Bank Balance (INR Cr) | 96 | 79 | 59 | 31 | 31 | 37 | 30 | 13 | 13 | 25 | 12 | 156 | 220 | 127 | 78 | 44 |
Total Debt (INR Cr) | 378 | 572 | 55 | 45 | 29 | 26 | 29 | 49 | 193 | 127 | 93 | 50 | 71 | 169 | 137 | 179 |
PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit As % Of Revenues | 15.5% | 12.9% | 15.5% | 20.4% | 14.9% | 11.4% | 9.5% | 13.3% | 12.7% | 8.6% | 5.7% | 8.9% | 43.0% | 15.2% | 15.4% | 3.5% |
Profit As % Of Assets | 16.6% | 13.4% | 17.4% | 23.9% | 18.4% | 12.8% | 9.3% | 12.9% | 11.7% | 8.9% | 5.4% | 7.4% | 64.6% | 16.1% | 16.9% | 4.0% |
Profit As % Of Networth | 18.9% | 16.5% | 18.1% | 24.8% | 19.0% | 13.1% | 9.6% | 13.5% | 13.7% | 10.1% | 5.9% | 7.9% | 70.6% | 20.4% | 21.1% | 5.5% |
Interest Cost to EBITDA % | 4.9% | 5.2% | 0.9% | 1.3% | 0.8% | 1.5% | 1.6% | 2.3% | 5.2% | 3.8% | 7.1% | 3.8% | 24.0% | 5.5% | 7.7% | 26.7% |
Debt to Equity Ratio | 0.13 | 0.23 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.04 | 0.16 | 0.13 | 0.09 | 0.05 | 0.07 | 0.25 | 0.24 | 0.38 |
RONW | 20.5% | 17.8% | 19.6% | 24.8% | 18.7% | 13.3% | 7.6% | 11.8% | 12.6% | 9.9% | 8.6% | 6.4% | 8.1% | 22.3% | 23.0% | 5.6% |
ROCE | 24.9% | 22.4% | 25.0% | 32.3% | 23.5% | 19.5% | 10.5% | 13.4% | 15.0% | 13.4% | 12.6% | 8.0% | 11.1% | 22.5% | 23.7% | 8.1% |